- Home
- MXE vs IMA Comparison
MXE vs IMA Comparison
Compare MXE & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MXE | IMA |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.7M | 66.3M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MXE | IMA |
|---|---|---|
| Price | $12.98 | $4.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 2.7K | ★ 12.1K |
| Earning Date | 01-01-0001 | 11-20-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.57 | $3.88 |
| 52 Week High | $14.30 | $8.84 |
Technical Indicators
Market Signals| Indicator | MXE | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 42.78 |
| Support Level | $12.79 | $3.91 |
| Resistance Level | $13.55 | $6.13 |
| Average True Range (ATR) | 0.27 | 0.22 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 70.59 | 39.48 |
Price Performance
Historical ComparisonAbout MXE Mexico Equity and Income Fund Inc. (The)
Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek high total return through capital appreciation and current income. It invests in equity securities, convertible securities and debt securities and may also invest in other securities such as capital development certificates, real estate investment trusts, mutual funds, exchange traded funds, preferred stocks, rights and warrants.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.